Ralph A. Reisfeld
#95,395
Most Influential Person Now
Ralph A. Reisfeld's AcademicInfluence.com Rankings
Ralph A. Reisfeldbiology Degrees
Biology
#4535
World Rank
#6753
Historical Rank
Immunology
#198
World Rank
#207
Historical Rank
Download Badge
Biology
Why Is Ralph A. Reisfeld Influential?
(Suggest an Edit or Addition)Ralph A. Reisfeld's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) (2185)
- Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. (2010) (1385)
- A procedure for rapid and sensitive staining of protein fractionated by polyacrylamide gel electrophoresis. (1967) (957)
- Tumor Regression by Targeted Gene Delivery to the Neovasculature (2002) (834)
- Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. (1994) (831)
- Antibody targeted drugs as cancer therapeutics (2006) (724)
- Targeting tumor-associated macrophages as a novel strategy against breast cancer. (2006) (560)
- DISC ELECTROPHORESIS IN POLYACRYLAMIDE GELS: EXTENSION TO NEW CONDITIONS OF pH AND BUFFER (1964) (555)
- Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. (2006) (514)
- Monoclonal antibodies and cancer therapy (1985) (489)
- Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. (1994) (424)
- A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth (2002) (413)
- Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. (1992) (395)
- Protein iodination with solid state lactoperoxidase. (1974) (391)
- Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. (1975) (385)
- Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model (2009) (381)
- T cell homeostatic proliferation elicits effective antitumor autoimmunity. (2002) (363)
- Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. (1984) (363)
- Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. (1983) (360)
- Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. (1982) (298)
- Electrophoretic Heterogeneity of Polypeptide Chains of Specific Antibodies (1966) (290)
- Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3 (1996) (237)
- Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. (1998) (237)
- An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2 (1987) (235)
- Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. (1987) (232)
- O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. (1984) (224)
- Salt Extraction of Soluble HL-A Antigens (1971) (223)
- A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. (1995) (215)
- Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. (2010) (213)
- Tumor‐Associated Macrophages Regulate Murine Breast Cancer Stem Cells Through a Novel Paracrine EGFR/Stat3/Sox‐2 Signaling Pathway (2013) (212)
- Inhibition of αvβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy (2005) (201)
- Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. (1998) (197)
- A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside. (1984) (194)
- Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. (1994) (194)
- Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. (1997) (191)
- Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. (1981) (187)
- Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. (1984) (183)
- Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. (1990) (183)
- Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. (1992) (182)
- Matrix metalloproteinase-2 activation modulates glioma cell migration. (1997) (181)
- Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. (2000) (181)
- An autologous oral DNA vaccine protects against murine melanoma. (2000) (179)
- Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. (1998) (178)
- Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. (1996) (167)
- Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. (2010) (163)
- Monoclonal antibodies in cancer immunotherapy. (1992) (162)
- Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. (2001) (162)
- T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy (1996) (159)
- Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies. (1984) (158)
- Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. (1989) (158)
- Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. (1991) (157)
- Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. (1990) (156)
- Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. (1988) (155)
- A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group (2006) (153)
- A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. (2005) (152)
- MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene (2014) (149)
- Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. (1997) (146)
- SOX2 Gene Regulates the Transcriptional Network of Oncogenes and Affects Tumorigenesis of Human Lung Cancer Cells (2012) (144)
- Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer (2011) (141)
- Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. (2000) (138)
- Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. (1999) (136)
- Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. (2004) (135)
- Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. (1987) (131)
- Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. (1986) (125)
- STUDIES ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITRO (1966) (125)
- Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. (1993) (124)
- Proteases and protease inhibitors in tumor progression. (1997) (122)
- Murine Ia and human DR antigens: homology of amino-terminal sequences. (1978) (122)
- A Dual-Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-Mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice1 (2001) (120)
- Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. (1991) (119)
- Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. (1992) (119)
- IFN-γ-Inducible Protein-10 Is Essential for the Generation of a Protective Tumor-Specific CD8 T Cell Response Induced by Single-Chain IL-12 Gene Therapy1 (2001) (118)
- Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. (1983) (118)
- Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. (2005) (115)
- KSA Antigen Ep-CAM Mediates Cell–Cell Adhesion of Pancreatic Epithelial Cells: Morphoregulatory Roles in Pancreatic Islet Development (1998) (110)
- Intralesional targeted alpha therapy for metastatic melanoma (2005) (108)
- A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. (1994) (108)
- Human tumor antigens. (1987) (107)
- Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. (1997) (105)
- Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. (1991) (104)
- Immunocytokines: a promising approach to cancer immunotherapy. (1998) (103)
- SEROLOGIC EVIDENCE FOR ANTIGENS CONTROLLED BY THE Ir REGION IN MICE (1973) (101)
- Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. (1996) (100)
- A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a (2005) (98)
- Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. (1998) (97)
- Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. (1984) (95)
- The Interleukins (1985) (95)
- Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. (1998) (95)
- Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. (1985) (95)
- Studies on human peripheral blood lymphocytes in vitro. I. Biological and physicochemical properties of the pokeweed mitogen. (1966) (95)
- Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. (1986) (94)
- Characterization of stem cell-like cancer cells in immune-competent mice. (2006) (94)
- An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. (1996) (93)
- Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma (2007) (89)
- Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. (1990) (89)
- A potential role for the plasmin(ogen) system in the posttranslational cleavage of the neural cell adhesion molecule L1. (1999) (89)
- Biologic and chemical characterization of HLA antigens in human serum. (1977) (88)
- Mouse models for melanoma: a personal perspective (2010) (87)
- Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy (2004) (86)
- A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis (2008) (85)
- Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. (1996) (85)
- The Role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression (2009) (85)
- Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. (1989) (84)
- SOX2 regulates apoptosis through MAP4K4-survivin signaling pathway in human lung cancer cells. (2014) (84)
- Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. (2005) (83)
- Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine (2003) (82)
- Production and regulation of gelatinase B by human T-cells. (1993) (81)
- Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. (1997) (80)
- Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. (2000) (78)
- Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. (1998) (78)
- Structural studies of murine I-E and human DR antigens. (1979) (77)
- Negative transcriptional regulation in anergic T cells. (1995) (76)
- Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). (1996) (75)
- Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. (1997) (75)
- A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. (1993) (74)
- Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin‐2 Induces Antibody‐Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro (1994) (74)
- Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. (1983) (74)
- The tumor microenvironment: a target for combination therapy of breast cancer. (2013) (73)
- Target cell‐induced T cell activation with bi‐ and trispecific antibody fragments (1991) (72)
- Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells (1985) (71)
- DNA Vaccination Against VEGF Receptor 2 Reduces Atherosclerosis in LDL Receptor–Deficient Mice (2007) (70)
- Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis (2008) (70)
- Integrin 4383 rescues melanoma cells from apoptosis in three-dimensional dermal collagen (69)
- Targeted cytokines for cancer immunotherapy (2000) (67)
- Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. (2001) (67)
- Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer (2006) (66)
- Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention (2012) (65)
- Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. (1983) (64)
- An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. (2001) (63)
- Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. (1986) (63)
- Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. (2007) (62)
- MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. (2001) (62)
- Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. (1990) (62)
- A rapid method for direct HL-A typing of cultured lymphoid cells. (1971) (62)
- Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma. (2000) (61)
- Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. (2011) (58)
- Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. (2001) (58)
- T cell memory against colon carcinoma is long-lived in the absence of antigen. (1999) (57)
- Tumor-associated antigens in spent medium of human melanoma cells: immunochemical characterization with xenoantisera. (1981) (56)
- Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53 (2013) (55)
- Evaluation of two sources of soluble HL‐A antigens: platelets and serum (1974) (55)
- Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. (1991) (55)
- Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. (1999) (54)
- IMD-0354 Targets Breast Cancer Stem Cells: A Novel Approach for an Adjuvant to Chemotherapy to Prevent Multidrug Resistance in a Murine Model (2013) (53)
- Multiple anomalous immunoglobulins. Clinical, structural and cellular studies in three patients. (1969) (52)
- Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells. (1984) (52)
- The lymphocytotoxic reaction: the mechanism of rabbit complement action. (1971) (52)
- Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue (2007) (52)
- The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. (2001) (52)
- Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. (2003) (52)
- Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma (1977) (51)
- Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. (2011) (51)
- A human brain glycoprotein related to the mouse cell adhesion molecule L1. (1988) (50)
- Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2 (1996) (50)
- Differences in amino acid composition of rabbit gamma-G-immunoglobulin light polypeptide chains controlled by allelic genes. (1965) (49)
- T cell-mediated suppression of angiogenesis results in tumor protective immunity. (2005) (49)
- Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. (1991) (49)
- Intratumoral immunocytokine treatment results in enhanced antitumor effects (2008) (49)
- NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy (2003) (49)
- Evaluation of C3 receptors on lymphoid cells with different complement sources. (1974) (49)
- Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. (2003) (49)
- Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. (1997) (49)
- DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. (2005) (48)
- Rabbit light chains lacking b-allotypic specificites. I. Isolation and characterization of light chains from normal and allotype suppressed homozygotes. (1969) (48)
- Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. (1995) (47)
- Vaccination Against VEGFR2 Attenuates Initiation and Progression of Atherosclerosis (2007) (47)
- The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. (1999) (47)
- Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. (1998) (46)
- Peptide differences of rabbit γG-immunoglobulin light chains controlled by allelic genes (1965) (46)
- DNA vaccines suppress tumor growth and metastases by the induction of anti‐angiogenesis (2004) (46)
- Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. (1996) (45)
- Monoclonal Antibodies in Cancer (1985) (45)
- Potential of the scid mouse as a host for human tumors (1991) (45)
- Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group (2017) (44)
- Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. (2000) (44)
- A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. (2006) (44)
- Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells. (1986) (43)
- Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. (1998) (43)
- A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. (2005) (42)
- Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice. (1993) (42)
- VARIATION IN SUSCEPTIBILITY OF A HUMAN LYMPHOID CELL LINE TO IMMUNE LYSIS DURING THE CELL CYCLE (1974) (42)
- Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. (1992) (41)
- Expression of HL-A antigens in synchronized cultures of human lymphocytes. (1972) (41)
- Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. (2000) (41)
- Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival (2013) (41)
- Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. (1995) (40)
- Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. (2012) (40)
- Characterization of Ia antigens in mouse serum. (1976) (40)
- Binding of proteins to CNBr‐activated sepharose 4B (1974) (40)
- HL-A antigens from a continuous lymphoid cell line derived from a normal donor. I. Solubilization and serologic characterization. (1970) (39)
- THE ANAMNESTIC ANTIBODY RESPONSE TO TYPE III SPECIFIC PNEUMOCOCCAL POLYSACCHARIDE (1969) (39)
- Vaccination against TIE2 reduces atherosclerosis. (2009) (39)
- Presensitization detected by sensitive crossmatch tests. (1973) (39)
- Chemical and immunochemical evidence for different classes of rabbit light polypeptide chains. (1968) (39)
- Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. (1998) (39)
- Purification and immunologic evaluation of human melnoma-associated antigens. (1978) (38)
- Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. (2006) (38)
- Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. (1998) (38)
- Antibody‐interleukin 2 fusion proteins: A new approach to cancer therapy (1996) (38)
- Purification of soluble human melanoma-associated antigens. (1976) (37)
- Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients (1995) (37)
- Activation of methotrexate-alpha-alanine by carboxypeptidase A-monoclonal antibody conjugate. (1992) (37)
- A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. (2004) (36)
- Recombinant antibody fusion proteins for cancer immunotherapy. (1996) (35)
- Lymphocyte-mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma. (1996) (35)
- A radioimmunometric antibody-binding assay for evaluation of xenoantisera to melanoma-associated antigens. (1979) (35)
- HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. (1976) (35)
- Activation of preexisting T cell clones by targeted interleukin 2 therapy. (1998) (35)
- Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. (1996) (34)
- Variations at the carboxyl-terminal amino acid sequence of rabbit light chains with b4, b5 and b6 allotypic specificities. (1969) (33)
- A novel 2'-(N-methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. (2002) (33)
- Differential internalization of hu14.18‐IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting (2011) (32)
- Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. (1996) (32)
- Subtypes of rabbit kappa light polypeptide chains associated with the beta locus. (1969) (32)
- An evaluation of the number of b4 allotypic determinants on rabbit gamma-G-immunoglobulin using double-labeled, soluble complexes with univalent antibody fragments. (1966) (31)
- Myelin‐Associated Glycoprotein Shares an Antigenic Determinant with a Glycoprotein of Human Melanoma Cells (1986) (31)
- INTERACTION OF HISTOCOMPATIBILITY (HL-A) ANTIBODIES AND COMPLEMENT WITH SYNCHRONIZED HUMAN LYMPHOID CELLS IN CONTINUOUS CULTURE (1973) (31)
- Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer (2011) (31)
- Physical association of histocompatibility antigens and tumor-associated antigens on the surface of murine lymphoma cells. (1979) (31)
- Targeting cancer with radiolabeled antibodies. (1995) (31)
- Human growth hormone: preparation from acetone powder. (1962) (30)
- Antigens associated with human squamous cell lung carcinoma defined by murine monoclonal antibodies. (1986) (30)
- Soluble HL‐A antigens in serum. I. Isolation and Purification (1975) (29)
- PURIFICATION AND CHARACTERIZATION OF SHEEP PROLACTIN (1961) (29)
- Serologic and immunochemical characterization of HLA-A9 xenoantisera. (1978) (28)
- DNA loops induced by cooperative binding of transcriptional activator proteins and preinitiation complexes. (1995) (28)
- β 2 -Microglobulins (1975) (28)
- Ammonium chloride interferes with a distinct step in the biosynthesis and cell surface expression of human melanoma-type chondroitin sulfate proteoglycan. (1986) (28)
- Cell-Associated Proteoglycans in Human Malignant Melanoma (1987) (28)
- Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities. (1998) (28)
- The association of the c7 allotype of rabbits with some light polypeptide chains which lack b locus allotypy. (1968) (27)
- Studies on human peripheral blood lymphocytes in vitro. V. Biosynthesis of immunoglobulins. (1968) (27)
- Stimulation of lymphocyte transformation by streptococcal type M1 protein: relationship to HL-A antigens. (1972) (27)
- Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2.27 conjugate directed to a human melanoma proteoglycan. (1988) (27)
- Fate of HL-A antigens in aging cultured human diploid cell strains. II. Quantitative absorption studies. (1973) (27)
- Melanoma Antigens and Antibodies (1982) (27)
- Immunogenicity of human B cell antigens solubilized from cultured human lymphoid cells. (1977) (27)
- A rapid microtechnique for in vitro stimulation of human lymphocytes by phytohemagglutinin. (1973) (27)
- Differences in amino acid composition related to allotypic and antibody specificity of rabbit IgG heavy chains (1968) (26)
- A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. (2006) (26)
- Water-soluble human transplantation antigen. (1968) (26)
- The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model (2011) (26)
- Immunogenicity of HLA antigens purified from serum. (1977) (25)
- Isolation and characterization of a mitogen from pokeweek (Phytolacca americana). (1967) (25)
- Purification of chorionic gonadotropin from the urine of patients with trophoblastic tumors. (1960) (25)
- Peptide maps of rabbit γG-immunoglobulin heavy chains controlled by Allelic Genes (1966) (25)
- IFN-g-Inducible Protein-10 Is Essential for the Generation of a Protective Tumor-Specific CD8 T Cell Response Induced by Single-Chain IL-12 Gene Therapy (2001) (25)
- Extraction and Purification of Soluble Histocompatibility Antigens (1971) (25)
- Multidrug resistance‐1 (MDR‐1): a new target for T cell‐based immunotherapy (2005) (24)
- Inhibition of post-translational modification and surface expression of a melanoma-associated chondroitin sulfate proteoglycan by diethylcarbamazine or ammonium chloride. (1986) (24)
- Serological and biochemical analyses of monoclonal antibodies to human melanoma-associated antigens. (1982) (24)
- Purification of porcine thyrocalcitonin. (1967) (24)
- Contemporary Topics in Molecular Immunology (1975) (24)
- Biological and chemical characterization of human histocompatibility antigens. (1970) (24)
- Antibody-coated protein A-bearing Staphylococcus aureus: a versatile and stable immune reagent. (1979) (24)
- Post-translational addition of chondroitin sulfate glycosaminoglycans. Role of N-linked oligosaccharide addition, trimming, and processing. (1989) (23)
- Electrophoretic purification of a water-soluble guinea pig transplantation antigen. (1967) (23)
- Human major histocompatibility complex class I antigens: residues 61-83 of the HLA-B7 heavy chain specify an alloreactive site. (1985) (23)
- FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice. (2007) (23)
- Isolation and chemical properties of porcine thyrocalcitonin. (1968) (22)
- HUMORAL SENSITIZATION IN PAROUS WOMEN: CYTOTOXIC ANTIBODIES TO NON HL‐A ANTIGENS (1976) (22)
- C3-mediated cytoadherence. Formation of C3 receptor aggregates as prerequisite for cell attachment (1975) (22)
- Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. (1993) (22)
- Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. (1996) (22)
- SEROLOGICAL CHARACTERIZATION OF NATURAL ANTIHUMAN LYMPHOCYTOTOXIC ANTIBODIES IN MAMMALIAN SERA (1973) (21)
- Association of HL‐A Antigens and β2‐Microglobulin: Concepts and Questions (1974) (21)
- Specificity of lymphocytotoxic anti-human antibodies in normal rabbit sera. (2008) (21)
- Current Trends in Histocompatibility (1981) (21)
- Human melanoma associated antigens: a solid-phase assay for detection of specific antibody. (1980) (21)
- DNA Vaccines Designed to Inhibit Tumor Growth by Suppression of Angiogenesis (2004) (21)
- In situ cytokine therapy: redistribution of clonally expanded T cells (2001) (21)
- C3 receptors on lymphoid cells: isolation of active membrane fragments and solubilization of receptor complexes. (1975) (21)
- Serologic cross-reactivity between H-2 and HL-A antigens. I. Specific reactivity of rabbit anti-HL-A sera against murine cells. (1972) (21)
- Human melanoma-associated antigens: role of carbohydrate in shedding and cell surface expression. (1981) (21)
- Water soluble guinea pig transplantation antigen from carcinogen-induced sarcomas. (1969) (20)
- Natural Killer Cell–Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy (1998) (20)
- Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. (2011) (20)
- Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro. (1990) (20)
- Immunochemical and biosynthetic analysis of monoclonal antibody-defined melanoma-associated antigen. (1982) (20)
- Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. (2003) (20)
- Transplantation antigens; markers of biological individuality (1972) (19)
- Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy. (1985) (19)
- Chemical modulation of cell surfaces by sulfhydryl compounds: effect on C3b receptors. (1974) (19)
- Approaches for the isolation of biologically functional tumor-associated antigens. (1977) (19)
- Continuous production of carcinoembryonic antigen in hollow fiber cell culture units: brief communication. (1978) (19)
- A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2 (1991) (19)
- Effect of inhibitors of macromolecular synthesis on HL-A antibody mediated lysis of cultured lymphoblasts. (2008) (18)
- Differences in the amino acid compositions of allogeneic guinea pig transplantation antigens. (1968) (18)
- CHARACTERIZATION OF SHEEP PROLACTIN. (1964) (17)
- Adenovirus Fiber Shaft Contains a Trimerization Element That Supports Peptide Fusion for Targeted Gene Delivery (2006) (17)
- Advances in the chemistry of transplantation antigens. (1969) (17)
- Chemical and immunochemical characterization of electrophoretic subfractions of rabbit gammaG-immunoglobulin light chains with b4 allotypic specificity. (1968) (17)
- Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera. (1973) (17)
- Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography. (1979) (17)
- Immunogenicity and partial purification of soluble H-2 antigens extracted with hypertonic salt. (1974) (17)
- Expression of H-2 antigens during growth of cultured tumor cells. (1972) (16)
- Detection of H-2 antigens in serum. (1975) (16)
- Distribution of gonadotropic hormone activity in the serum proteins of normal pregnant women and patients with trophoblastic tumors. (1959) (16)
- Expression of HL-A antigens on the surface of cultured human lymphoid cells: effect of inhibitors of protein and nucleic acid synthesis. (2008) (15)
- Quantitative serologic parameters of purified HL-A antigens. (1971) (15)
- Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study (2008) (15)
- Monoclonal antibodies to human malignant melanoma (1982) (15)
- Biosynthesis and glycosylation of the carcinoma-associated antigen recognized by monoclonal antibody KS1/4. (1990) (15)
- Structural polymorphism of the β chain of human HLA-DR antigens (1980) (15)
- Isolation, chemical and immunologic characterization of kappa and lambda-type light chains from IgG of normal rabbits with b9 allotype. (1970) (15)
- Contemporary Topics in Molecular Immunology (1974) (14)
- Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. (1978) (14)
- Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects1 (2006) (14)
- Chemical markers of transplantation individuality solubilized with sonic energy. (1971) (13)
- A QUANTITATIVE STUDY OF CROSS REACTIVITY IN THE HL‐A SYSTEM WITH HUMAN CULTURED LYMPHOID CELLS AND SOLUBLE HL‐A ANTIGENS (1973) (13)
- The Quantitative Expression, Genetics and Chemistry of Allotypes, Types and Subtypes of Rabbit Light Polypeptide Chains (1970) (13)
- Determination of the number of e-amino groups available for conjugation of effector molecules to monoclonal antibodies. (1988) (13)
- Utilization of cultured human lymphoid cells for detection of humoral sensitization in prospective recipients of kidney transplants. (1975) (13)
- Semi-automatic solid-phase radioimmunoassay for carcinoembryonic antigen. (1977) (13)
- The immunologic and molecular profiles of HLA antigens isolated from urine. (1977) (13)
- DNA vaccines suppress angiogenesis and protect against growth of breast cancer metastases. (2004) (12)
- Tid1 Is Required for T Cell Transition from Double-Negative 3 to Double-Positive Stages 1 (2005) (12)
- Human tumor-associated antigens defined by monoclonal antibodies. (1984) (12)
- Association of HL-A antigens andβ2-microglobulin at the cellular and molecular level (1975) (12)
- Differences in amino acid composition of papain Fd fragments from rabbit γG-immunoglobulins carrying different H chain allotypic specificities (1968) (12)
- Biochemical characterization of a sulfated phosphoglycoprotein antigen expressed on human small cell lung carcinoma. (1988) (12)
- N-terminal amino acid sequences of the alpha and beta chains of HLA-DR1 and HLA-DR2 antigens. (1983) (12)
- Superantigen-staphylococal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells (1995) (12)
- The expression of HL-A antigens during the growth cycle of cultured human lymphoid cells. (1973) (12)
- Molecular profiles of human melanoma-associated antigens. (1981) (12)
- Immunochemical delineation of an oncofetal antigen on normal and simian virus 40-transformed human fetal melanocytes. (1981) (12)
- Amino acid composition of rabbit IgG light chains with b6 allotypic specificity (1968) (12)
- Anti-HLA antibodies of predetermined specificity: a chemically synthesized peptide induces antibodies specific for HLA-A,B heavy chain. (1983) (12)
- Human Histocompatibility Antigens (1972) (11)
- Lysis of neuroblastoma cells by the ADCC-reaction: granulocytes of patients with chronic granulomatous disease are more effective than those of healthy donors. (1989) (11)
- Immunogenicity of soluble HL-A alloantigens. (1972) (11)
- Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors (2019) (11)
- Heterogeneity of Rabbit Light-Polypeptide Chains (1967) (11)
- The role of complement in the HL-A antibody-mediated lysis of lymphocytes. (1974) (11)
- Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy. (1994) (10)
- Effects of granulocytes on human neuroblastoma cells measured by chemiluminescence and chromium-51 release assay. (1989) (10)
- A Biologic and Chemical Profile of Histocompatibility Antigens (1975) (10)
- Current Status and Future Perspectives of Chemoimmunoconjugates for the Treatment of Cancer (1990) (10)
- Semi-automatic solid-phase double-antibody radioimmunoassay for beta2-microglobulin. (1976) (10)
- Extraction and purification of soluble HL-A antigens from exhausted media of human lymphoid cell lines. (1973) (10)
- Hypertonic Salt Extraction of HL-A Antigens: Assessment of Protease Activity 1 (1974) (10)
- Chapter 15 Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotheraphy (1994) (9)
- Application of the murine anti-Gd-2 antibody 14.Gd-2a for diagnosis and therapy of neuroblastoma. (1991) (9)
- What to do with targeted IL-2. (2000) (9)
- Pre-clinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells (1991) (9)
- Expression of histocompatibility antigens during the growth cycle of cultured lymphoid cells. (1974) (9)
- Markers of biological individuality. (1972) (9)
- Direct demonstration and quantitatin of Aal, Aa2 and Aa3 allotypic specificities on Fd-fragments of rabbit immunoglobulin G. (1968) (8)
- Immunogenicity of Electrophoretically Purified Guinea Pig Transplantation Antigen (1969) (8)
- Rabbit immunoglobulin lambda chains: isolation and amino acid sequence of cysteine-containing peptides. (1974) (8)
- CHAPTER 24 – THE MOLECULAR NATURE OF HL-A ANTIGENS (1972) (8)
- Chemical properties of porcine thyrocalcitonin. (1967) (8)
- Binding of carcinoembryonic antigen (CEA) to concanavalin A-sepharose: storage of high-specific-activity 125I-CEA. (1974) (8)
- Cross-reactivity between HL-A and H-2 antigens. II. Allogeneic sensitization by xenogeneic soluble lymphocyte antigens (HL-A). (1973) (8)
- Potential of genetically engineered monoclonal antibodies for cancer immunotherapy. (2008) (8)
- Association of human and bovine beta 2-microglobulins with detergent solubilized HLA-A,B antigens. (1982) (7)
- Serologic specificity and crossreactivity of soluble HL-A alloantigens. (1972) (7)
- Typing of cultured human lymphoid cells. (1972) (7)
- Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes (2005) (7)
- A recurrent idiotype on monoclonal anti-human Ia antibodies (1982) (7)
- The antigenic stimulus in human transplantation. (1973) (7)
- The Ch 14 . 18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro 1 (1999) (7)
- Amplification of T Cell-Mediated Immune Responses by Antibody-Cytokine Fusion Proteins (2000) (7)
- Characterization and Isolation of HL-A Antigens from Continuous Cultured Human Lymphocyte Cell Lines: A Report of Current Progress (1972) (7)
- Chemical and molecular nature of HL-A antigens. (1973) (7)
- Molecular probes : technology and medical applications (1989) (6)
- Distinction between malignant L cells and normal mouse fibroblasts by rosette formation with sheep red blood cells. (1975) (6)
- Inhibitory effect of normal mammalian sera on the rosette formation of human lymphocytes with sheep red blood cells. (1975) (6)
- Expression of HL-A antigens on cultured human fibroblasts infected with mycoplasmas. (1973) (6)
- Cross-reactivity between human and murine lymphocyte antigens: III. Reactivity of H-2 allo- and xenoantisera with human lymphoid cells (1974) (6)
- A simple method for production of specific xenoantisera to human histocompatibility (HLA-A,-B,-C) antigens. (1978) (6)
- Monoclonal Antibodies as Probes for the Molecular Structure and Biological Function of Melanoma-Associated Antigens (1985) (5)
- Separation of 7Sγ1-Globulin, 7Sγ2-Globulin and Macroglobulin Guinea Pig Antibodies (1966) (5)
- Cytokine fusion protein treatment. (2002) (5)
- Human histocompatibility antigens: isolation and chemical characterization. (1982) (5)
- A simplified cloning strategy for the generation of an endothelial cell selective recombinant adenovirus vector. (2006) (5)
- Report of the International Consensus Conference on Human Melanoma Antigens, Lausanne, Switzerland, 12-14 November, 1992. (1993) (5)
- Lack of association of serologically detectable human melanoma-associated antigens with beta 2 microglobulin: serologic and immunochemical evidence. (1980) (5)
- Isolation and Serological Evaluation of HL-A Antigens Solubilized from Cultured Human Lymphoid Cells (1974) (5)
- [The role of interferons in neuroblastoma. 2: Immunomodulatory effects]. (1990) (5)
- Genotypes of NK cell KIR Receptors , Their Ligands , and Fc γ Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy : A Children ’ s Oncology Group Report # (2010) (5)
- The major histocompatibility complex in man: biological and molecular approaches. (1976) (4)
- Detection of Ganglioside GD 2 in Tumor Tissues and Sera of Neuroblastoma Patients 1 (2006) (4)
- A high yield purification procedure for alpha and beta chains of HLA-DR antigens. (1982) (4)
- CELLULAR AND MOLECULAR HETEROGENEITY OF H‐2Kk ANTIGENS (1981) (4)
- NF-úB Inhibitor IMD-0354 Targets Human Non-Small Cell Lung Cancer Stem Cells and Combined with Chemotherapy Reduces Multidrug Resistance (2013) (4)
- Immunochemical characterization of human tumor antigens. (1986) (4)
- CHAPTER 11 – SALT EXTRACTION OF SOLUBLE HL-A ANTIGENS (1972) (4)
- Therapeutic efficacy of tumor-targeted IL2 in LTα−/− mice depends on conditioned T cells (2006) (4)
- Effects of inhibitors of macromolecular synthesis on cell surface expression of HL-A antigens. (1973) (4)
- Delayed cutaneous hypersensitivity to cell-free tumor antigens. (1973) (4)
- Disialoganglioside GD 2 on Human Neuroblastoma Cells : Target Antigen for Monoclonal Antibody-mediated Cytolysis and Suppression of Tumor Growth 1 (2006) (3)
- A study of the calcium-binding properties of whole casein, [alpha]-casein, and [beta]-casein / (1957) (3)
- Identification of the Pokeweed Mitogen in Africa (1967) (3)
- Indirect rosette microassay: comparison of protein a with purified anti-Ig antibody (1980) (3)
- Expression of a sheep red blood cell receptor by a murine lymphoma. (1979) (3)
- Immune response to soluble H-2Kd antigens. (1974) (3)
- MIG ( CXCL 9 ) Chemokine Gene Therapy Combines with Antibody-Cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma 1 (2001) (3)
- Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial. (2016) (3)
- A Phase I Trial of Immunocytokine HU14.18-IL2 in Children with Recurrent or Refractory Neuroblastoma and Other GD2 Positive Malignancies: A Study of the Children's Oncology Group (2004) (3)
- The cell surface : immunological and chemical approaches : [proceedings of an international conference held at Brook Lodge, Augusta, Michigan, June 17-20, 1974] (1974) (2)
- Erratum: An autologous oral DNA vaccine protects against murine melanoma (Proceedings of the National Academy of Sciences of the United States of America (May 9, 2000) 97 (10) (5492-5497)) (2000) (2)
- Antibody-Drug Conjugates for Cancer Therapy (1991) (2)
- Structural Analyses of HLA-DR Antigens (1981) (2)
- An affinity adsorbent for the rapid purification of wheat germ agglutinin. (1975) (2)
- International Conference on the Biology of Melanoma. Aviano, Italy, 24-26 September 1995. (1996) (2)
- Molecular and Immunological Characterization of Human Melanoma-Associated Antigens (1982) (2)
- Fifth Annual Sapporo Cancer Seminar. Monoclonal antibodies--progress in cancer immunobiology and clinical application. (1986) (2)
- Disialoganglioside GD 3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis ( melanoma ganglioside antigen / cytolysis / immunotherapy ) (2003) (2)
- H-2 and ia antigens in mouse serum. Abstr. (1976) (2)
- Molecular profile of human melanoma associated antigens purified from spent culture medium (1979) (2)
- An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. (1977) (2)
- New Approaches to Cancer Immunotherapy (1989) (2)
- Immunotherapy of cancer: A perspective view (1988) (2)
- Evaluation of immunogenic and tolerogenic properties of soluble h-2 antigen. Abstr. (1972) (2)
- IS SEROLOGICAL POLYMORPHISM OF HUMAN DR ANTIGENS DETERMINED BY STRUCTURAL DIFFERENCES IN THE SMALLER (β) CHAIN (1979) (2)
- The Major Histocompatíbility Complex in Man: Biological and Molecular Approaches (Part 1 of 2) (1976) (2)
- National Pancreatic Cancer Project Workshop on Pancreatic Tumor Markers (2005) (2)
- Gonadotropic hormone distribution in protein extracts of trophoblastic tumors in man. (1960) (1)
- Protein Iodination with Solid State Lactoperoxidaset (1)
- Clinical and immune responses in metastatic melanoma patients immunized with an anti-idiotype (anti-Id) monoclonal antibody (mAb) mimicking disialoganglioside gd21 (1999) (1)
- Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. (1977) (1)
- Transplantation Antigens (1970) (1)
- Metalloproteinase-2 Activation and Cell Surface Association of Matrix Remodeling of Collagen Matrix by Human Tumor Cells Requires Updated (2006) (1)
- An oral vaccine against the tumor-stromal antigen FAP (fibroblast activation protein) inhibits growth of chemo-resistant murine colon-carcinoma (2004) (1)
- Structural polymorphism of the beta chain of human HLA-DR antigens. (1980) (1)
- Production of Anti‐W24 Xenoantisera in Rabbits1 (2008) (1)
- The role of interferon-gamma in the immunotherapy of neuroblastoma. (1991) (1)
- Abstract 1538: Enhanced antitumor effects of intratumoral (IT) hu14.18-IL2 immunocytokine (IC) compared to intravenous (IV) hu14.18-IL2 are distinguished by increased activated tumor infiltrating lymphocytes (TILs) and IC retention (2012) (1)
- BIOCHEMICAL AND FUNCTIONAL PROFILES OF TWO UNIQUE MELANOMA ASSOCIATED ANTIGENS (1985) (1)
- BIOSYNTHETIC STUDIES ON FIBRONECTIN AND CHONDROITIN SULPHATE PROTEOGLYCANS IN HUMAN MELANOMA CELLS (1982) (1)
- Activation of the Alternate Pathway of C by Human Histocompatibility (HL-A) Antibodies (1973) (1)
- Antigen repertoire of human melanoma. (1988) (1)
- An Oral DNA Vaccine Encoding Endoglin Eradicates Breast Tumors by Blocking Their Blood Supply (2006) (1)
- Cultured human lymphoid cells: Tools for the biological and molecular characterization of antigens and their recognition systems (1975) (1)
- Mechanism of Immunocytokine Therapy Adenocarcinoma Can Change the Antitumor Effector The Level of MHC Class I Expression on Murine Updated (2001) (1)
- Production of anti-W24 xenoantisera in rabbits. (1975) (1)
- Metalloproteinase-dependent Proteolytic Pathways Contribution of Urokinase-dependent and Melanoma-mediated Dissolution of Extracellular Matrix : Updated Version (2006) (1)
- Antigenic expression of human melanoma cells in serum-free medium. (1984) (1)
- Induction of cellular immunity against VEGFR2 by DNA vaccination attenuates atherosclerosis (2006) (1)
- Contemporary Topics in Molecular Immunology (1981) (0)
- Advances in Brief Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic flu / flu Mice by an Antibody-Lymphotoxin Fusion Protein 1 (2006) (0)
- Abstract 4232: Tumor-associated macrophages are responsible for EGF-R triggered upregulation of the Sox-2 signaling pathway in CSCs, which enhance tumorigenicity and tumor metastasis (2010) (0)
- Doxorubicin conjugated withamonoclonal antibody directed toa humanmelanoma-associated proteoglycan suppresses the growth ofestablished tumorxenografts innudemice (immunotherapy ofhumanmelanoma/immunoconjugates) (1988) (0)
- Cancer Therapy: Monoclonal Antibodies, Lymphokines : New Developments in Surgical Oncology and Chemo-And Hormonal Therapy (1989) (0)
- Abstract 263: Silence of SOX2 induces apoptosis through both mitochondria and death receptor signal pathway by activating the RAS/MAPK signals in human lung cancer cells (2012) (0)
- Abstract 2828: miR-19a-3p inhibits breast carcinoma metastasis via reversing M2 phenotype of TAMs. (2013) (0)
- Procedures for treating tumors and metastases using a combination of therapies and immunotherapies Antiangiogenic. (2000) (0)
- Report of the second annual walker's cay colloqium on cancer vaccines and immunotherapy, March 8-11, 2000. (2000) (0)
- Carcinoma Metastases SCID Mouse Models of Prostate and Colon Antibody-IL-12 Fusion Proteins Are Effective in (1998) (0)
- 1 Overview of cancer research with monoclonal antibodies (1987) (0)
- Bone Marrow by Targeted Interleukin-2 Therapy Mediated Eradication of Neuroblastoma Metastases to - Natural Killer Cell (2013) (0)
- Summary of three phase I/II trials using anti-disialoganglioside (GD2) monoclonal antibodies in neuroblastoma-therapy (2007) (0)
- COMBINED IMMUNOLOGIC THERAPY WITH INTERLEUKIN-2 AND ANTI-GD-2 MONOCLONAL ANTIBODY 14.G2a INDUCES IN VIVO IMMUNOLOGIC CONDITIONS ABLE TO MEDIATE ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN VITRO, IN PEDIATRIC NEUROBLASTOMA PATIENTS (1992) (0)
- Editorial (0)
- Immunotherapy Targeting Tumor Stromal Fibroblasts Improves Chemotherapy of Breast Cancer (2007) (0)
- Breast cancer and neuroblastoma models for the in vivo study of stem cell like cancer cells in immune competent mice (2006) (0)
- Editorial (0)
- FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (2017) (0)
- Clinical a nd I mmune R esponses i n A dvanced M elanoma Patients I mmunized W ith a n A nti-Idiotype A ntibody Mimicking D isialogangliosi de G D2 (2000) (0)
- The Biological and Molecular Profile of Human Histocompatibility Antigens (1979) (0)
- ADNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor. Commentary (2006) (0)
- Histocompatibility Antigens: Characterization (1971) (0)
- Eradication ofhumanhepatic andpulmonary melanoma metastases inSCIDmicebyantibody-interle (1996) (0)
- Immunotherapy of Melanoma with Monoclonal Antibody-Drug Conjugates (1990) (0)
- Idiotipy of monoclonal antibodies to HLA-DR antigens as a means for further definition of HLA-DR antibodies (1982) (0)
- Peptide maps of rabbit gamma-G-immunoglobulin heavy chains controlled by allelic genes. (1966) (0)
- Session I: Translational research - DNA vaccines and immunocytokines for cancer therapy (2003) (0)
- Solubilization and Expression of Surface Components (1974) (0)
- A novel approach for testing the immunointegrity of radiolabeled antibodies (1984) (0)
- Immunology 1868, proceedings of the international convocation on immunology Buffalo, N.Y., June 1968 - Edited by N.R. Rose and F. Milgrom. S. Karger, A. G. Basel, New York, 1969. 361 pp., $24.00. (1971) (0)
- Biological and clinical concepts (1981) (0)
- The Major Histocompatíbility Complex in Man: Biological and Molecular Approaches (Part 2 of 2) (1976) (0)
- Chapter 9.6 Cell Surface Antigens (1983) (0)
- Immunology 2007 (2008) (0)
- Transplantaton antigens. (1969) (0)
- Abstract 1914: Cross-talk between breast cancer cells and tumor-associated macrophages leads to tumor cell invasion, angiogenesis and metastasis (2010) (0)
- Pre-clinical models for immunotherapy of melanoma. (1989) (0)
- Antibody against Ir-region controlled antigen in mice (1973) (0)
- Interferon-Gamma Up-Regulates the Susceptibility of Human Neuroblastoma Cells to Natural Killer Cell-Mediated and Antibody-Dependent Cellular Cytotoxicity1 (1990) (0)
- Utilization of xeno anti sera to bone marrow derived cell antigens to determine their serological and molecular properties (1977) (0)
- Targeting Tumor Associated Fibroblasts and Chemotherapy (2011) (0)
- Activation ofHumanComplement byHumanLymphoid Cells Sensitized withHistocompatibili ty Alloantisera* (membrane/cytotoxic test) (1973) (0)
- Memory T cells: death by acquisition (2007) (0)
- Chairmen’s Overview on the Use of Immunoanalytical Method for the Characterization and Quantification of DNA Components Structurally Modified by Carcinogens and Mutagens (1983) (0)
- Potential Use of Bispecific Antibodies (BSABS) for Targeting Gliomas and Melanomas (1996) (0)
- Immunogenetic and molecular profiles (1981) (0)
- Monoclonal antibodies and cancer therapy : proceedings of the Roche-UCLA Symposium held in Park City, Utah, January 26-February 2, 1985 (1985) (0)
- Immunochemotherapy of Cancer: A Perspective (1989) (0)
- PRECLINICAL TESTING AND DEVELOPMENT OF CHIMERIC/HUMANIZED ANTI-GD2-INTERLEUKIN 2 FUSION PROTEIN (1997) (0)
- Mo-W12:4 Vaccination against VEGFR2 attenuates both the initiation and progression of atherosclerosis (2006) (0)
- Activated matrix metalloproteinase-2 governs tumor cell migration and invasion (1997) (0)
- Award Number: W81XWH-06-1-0310 TITLE: Immunotherapy Targeting Tumor Stromal Fibroblasts Improves Chemotherapy of Breast Cancer (2007) (0)
- Development of Herpetic Stromal Keratitis Receptor 2-Based DNA Immunization Delays Vascular Endothelial Growth Factor (2013) (0)
- Separation of 7S gamma-1-globulin, 7S gamma-2-globulin and macroglobulin guinea pig antibodies. (1966) (0)
- [Not Available]. (1948) (0)
- Immune response to soluble h-2 antigen, humoral unresponsiveness in the presence of cellular immunity. Abstr. (1973) (0)
- COMMUNICATIONS (1967) (0)
- Double-Negative 3 to Double-Positive Stages Tid 1 Is Required for T Cell Transition from (2005) (0)
- Abstract 3342: Overexpression of transcription factor Fra-1 drives murine 4TO7 breast cancer stem cells out of dormancy and render them sensitive to chemotherapy (2011) (0)
- Award Number: W81XWH-10-1-0764 TITLE: Priming the tumor immune microenvironment improves immune surveillance of cancer Stem cells and prevents cancer recurrence PRINCIPAL INVESTIGATOR: (2012) (0)
- Expression of HL-A Antigens on Lymphoblastoid Cells (1975) (0)
- Mono clonal antibodies to hla dr inhibit the growth of human melanoma cells in soft agar (1982) (0)
- IMMUNOTHERAPY OF CANCER; DISAPPOINTING OR STILL PROMISING? AN OVERVIEW (1994) (0)
- Immunocytokines: Versatile Molecules for Biotherapy of Malignant Disease (2003) (0)
- A DNA vaccine against tumor stromal antigen FAP boosts chemotherapy leading to tumor rejection (2005) (0)
- Functional Activity of a Recombinant Anti-Ganglioside GD2-IL2 Fusion Protein (1994) (0)
- In-situ cytokine therapy by immunokines: Induction of T-cell mediated antitumor immunity (1997) (0)
- Isolation, Chemical and Immunologic Characterization of κ- and λ-Type Light Chains from IgG of Normal Rabbits with b9 Allotype (1970) (0)
- Targeted cytokine delivery with recombinant antibody fusion proteins for therapeutic intervention (1997) (0)
- Unique glycoprotein antigen defined by monoclonal antibody on human neurobiastoma cells (1986) (0)
- Contemporary Topics in Molecular Immunology (1978) (0)
- Activation ex vivo de cellules effectrices pour la destruction des cellules cibles (1987) (0)
- THE PURIFICATION AND BIOLOGICAL DETECTION OF A WATER-SOLUBLE GUINEA PIG TRANSPLANTATION ANTIGEN (1968) (0)
- A Biochemical and Biosynthetic Analysis of Human Melanoma-Associated Antigens with Monoclonal Antibodies (1983) (0)
- Monoclonal antibody and an antibo surface proteoglycan of melanoma tumor growth (immunotherapy of human melanoma/antibody immunotherapy of tu (2016) (0)
- Molecular and biological profiles of two unique antigens associated with human melanoma (1985) (0)
- A DNA-based cancer vaccine enhances lymphocyte crosstalk by engaging the NKG2D receptor Running Title: Engaging NKG2D receptor enhances crosstalk (2005) (0)
- P-16 Regression of melanoma by tumour anti-vascular alpha therapy (2007) (0)
- Adhesion Molecules as Drug Targets. The Case of CD2 (1997) (0)
- Structural Analysis of Murine and Human Ia Alloantigens (1978) (0)
- Suppression of Human Melanoma Metastasis in SCID Mice with Antibodies to the EGF-Receptor (1994) (0)
- Abstract 3366: An inhibitor of the NF-kappaB pathway targets cancer stem cells and prevents tumor recurrence (2012) (0)
- T cell-mediated suppression of angiogenesis results in tumor protective immunity. Commentary (2005) (0)
- Current trends in histocompatibility. Volume 2. Biological and clinical concepts. (1981) (0)
- Classification : Neoplasia Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug resistant T-cell leukemia (2003) (0)
- Endoglin(CD105) is an effective target for an oral DNA vaccine against breast cancer (2005) (0)
- Isolation and ImmunochemicalCharacterization of Antibodies from the Seraof CancerPatientsWhichAre ReactiveagainstHumanMelanoma Cell Membranesby AffinityChromatography1 (1979) (0)
- DNA composition to the tumor antigen FAP stromal and methods thereof utlización (2007) (0)
- W12-P-028 Vaccination against VEGF receptor 2 blocks initiation and progression of atherosclerosis (2005) (0)
- Unique glycoprotein-proteoglycan antibody on human melanoma cells (melanoma antigen complex/biosynthesis) (2016) (0)
- IMMUNOGENICITY OF HLA ANTIGENS PURIFIED FROM SERUM1 (1977) (0)
- Specific sialyltransferase is responsible for the synthesis of GD/sup 3/, a ganglioside preferentially expressed on human metastatic melanoma cells (1986) (0)
- Clinical Studies Genotypes of NK Cell KIR Receptors , Their Ligands , and Fc g Receptors in the Response of Neuroblastoma Patients to Hu 14 . 18-IL 2 Immunotherapy (2010) (0)
- Immunogenicity of murine major histocompatibility products in serum. Abstr. (1978) (0)
- Carcinoembryonic Antigen-Transgenic Mice Immunity Against Colon Cancer in Trimer Induces T Cell-Mediated Protective Carcinoembryonic Antigen and CD 40 Ligand A Dual-Function DNA Vaccine Encoding (2001) (0)
- Addition of systemic IL2 increases effectiveness of hu14.18-IL2 immunocytokine therapy against NXS2 murine neuroblastoma (2004) (0)
- An Immunochemical Approach to the Isolation of Human Melanoma-Associated Antigens (1982) (0)
- Abstract 5614: Legumain protease substrate modified TAT-liposome cargo: an efficient tool for targeting malignant diseases. (2013) (0)
- Anticorps monoclonal destine au ganglioside gd2 humain (1985) (0)
- [Biological and chemical aspects of histocompatibility antigens in serum]. (1976) (0)
- Rabbit Light Chains Lacking b-Allotypic Specificities (1969) (0)
- MDR-1 Recognition by Cytotoxic T Cells. (2004) (0)
- PEPTIDE DIFFERENCES OF RABBIT GAMMA-G-IMMUNOGLOBULIN LIGHT CHAINS CONTROLLED BY ALLELIC GENES. (1965) (0)
- This information is current as Well As Enhanced IC Retention Involve Both Activated T and NK Cells As Local and Systemic Antitumor Effects That IL-2 (IC) Induces - Intratumoral hu14.18 (2017) (0)
- Long-Term Growth Suppression of Human Glioma Xenografts by Chemoimmunoconjugates of 4-Desacetylvinblastine-3- carboxyhydrazide and Monoclonal Antibody 9.2.271 (2006) (0)
- P12 Immune responses in melanoma patients immunized with an anti-idiotype (Id) antibody mimicking GD2 (1999) (0)
- Lymphokine-Activated Human Effector Cells Targeted by Monoclonal Antiganglioside Antibodies: A Preclinical Model for Immunotherapy of Human Melanoma (1989) (0)
- Editorial (0)
- I N T E R a C T I O N of H I S T O C O M P a T I B I L I T Y (2003) (0)
- TUMORS IN OF ESTABLISHED HUMAN MELANOMA NUDE MICE BY ANTIBODY-DIRECTE D EFFECTOR CELLS (1985) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ralph A. Reisfeld?
Ralph A. Reisfeld is affiliated with the following schools:
